Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire    SHP   JE00B2QKY057

SHIRE (SHP)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/17/2017 10/18/2017 10/19/2017 10/20/2017 10/23/2017 Date
3839(c) 3719.5(c) 3748.5(c) 3677.5(c) 3672.5(c) Last
2 463 512 3 733 832 2 803 444 2 681 931 1 219 445 Volume
-2.08% -3.11% +0.78% -1.89% -0.14% Change
More quotes
Financials ($)
Sales 2017 14 958 M
EBIT 2017 5 579 M
Net income 2017 2 572 M
Debt 2017 19 245 M
Yield 2017 0,74%
Sales 2018 15 552 M
EBIT 2018 6 068 M
Net income 2018 3 364 M
Debt 2018 15 299 M
Yield 2018 0,83%
P/E ratio 2017 16,51
P/E ratio 2018 11,87
EV / Sales2017 4,23x
EV / Sales2018 3,82x
Capitalization 44 061 M
More Financials
Company
Shire Plc is a biopharmaceutical company.The company focuses on developing and marketing innovative medicines for patients with rare diseases and other conditions.It engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of innovative specialist medicines... 
Sector
Pharmaceuticals
Calendar
10/27 | 01:00pmEarnings Release
More about the company
Surperformance© ratings of Shire
Trading Rating : Investor Rating :
More Ratings
Latest news on SHIRE
10/23 SHIRE : to Present New Data to Help Advance Understanding of Rare Diseases
10/19 SHIRE : Create the Soundtrack to Your Unique Day with “Compose Your Life&r..
10/18 FTSE rises to record close, blue-chips shrug off Reckitt blip
10/17 SHIRE : New Formulation of ONCASPAR Receives Positive CHMP Opinion in Europe for..
10/14 SHIRE : Activist fund seeks break-up of £35bn pharma group Shire
10/13 SHIRE PLC : New Formulation of ONCASPAR® (pegaspargase) Receives Positive CHMP O..
10/13 SHIRE : New Formulation of ONCASPAR® (pegaspargase) Receives Positive CHMP Opini..
10/12 SHIRE PLC : Financial Statements and Exhibits (form 8-K)
10/12 SHIRE : to announce third quarter 2017 results
10/12DJSHIRE PLC SHIRE PLC : Notice Of Results
More news
Sector news : Pharmaceuticals - NEC
10/23 European stocks hold firm as banks, Spanish shares fall
10/23 Smith & Nephew to buy Rotation Medical for up to $210 million
10/23DJEuropean Corporate Roundup for Monday
10/23DJDrug Makers Find 'Branded Generics' Are a Source for Growth
10/23 ASTRAZENECA : among backers as Swiss cancer biotech raises $200 million
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on SHIRE 
SHIRE - 2015
Sellers pressure likely to dominate
SELL
SHIRE - 2014
Benefit from the resuming bullish trend
BUY
More Strategies
Latest Tweets
10/23Shire to Present New Data to Help Advance Understanding of Rare Diseases  
10/23Shire : to Present New Data to Help Advance Understanding of Rare Diseases  
10/23Shire of Donnybrook Balingup : Household Hazardous Waste  
10/21Shire PLC $SHPG Now Covered by FBR & Co  
10/21Shire PLC $SHPG Now Covered by FBR & Co  
More tweets
Qtime:146
News from SeekingAlpha
10/20 Debt-laden pharmas under pressure on Concordia's debt restructuring
10/19 Premarket analyst action - healthcare
10/18 Generic Restasis Risk Metastasizes To Shire
10/18 Shire feels Amgen's Restasis patent pain, shares down 3%
10/16 YOUR DAILY PHARMA SCOOP : ACRX Second Chance, AERI Rhopressa Success, Aratana EN..
Chart SHIRE
Duration : Period :
Shire Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Technical analysis trends SHIRE
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 69,0 $
Spread / Average Target 42%
EPS Revisions
Managers
NameTitle
Flemming Ornskov Chief Executive Officer & Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
Jeffrey Poulton Chief Financial Officer & Executive Director
Philip J. Vickers Global Head-Research & Development
Matt Walker Head-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE-21.49%43 958
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.97%226 404
PFIZER12.13%216 886
ROCHE HOLDING LTD.0.77%207 116
MERCK AND COMPANY8.51%174 223